Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02884102 · ClinicalTrials.gov registry record

MMRF Molecular Profiling Protocol

A clinical trial of Multiple Myeloma and Plasma Malignancy, sponsored by Multiple Myeloma Research Foundation.

Active
Registry status
1,000
Enrollment target
20
Study locations

NCT02884102 is a study of Multiple Myeloma and Plasma Malignancy that is active but no longer recruiting, run by Multiple Myeloma Research Foundation. The registered enrollment target is 1,000 participants, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% higher). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02884102, a study of Multiple Myeloma and Plasma Malignancy, is active but no longer recruiting, sponsored by Multiple Myeloma Research Foundation.

ACTIVE NOT RECRUITING
Registry status
1,000 participants
Enrollment target
20
Study locations

Study Summary

This protocol is now being used as screening for the MyDRUG study

Interventions

  • GENETIC genetic sequencing

Study Locations (20)

California

  • City of Hope - Duarte
  • UCSF Medical Center - San Francisco

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Michigan

  • University of Michigan - Ann Arbor
  • Barbara Ann Karmanos Cancer Institute - Detroit

Arizona

  • Mayo Clinic - Scottsdale - Scottsdale

Florida

  • Mayo Clinic - Jacksonville - Jacksonville

Georgia

  • Emory University - Atlanta

Illinois

  • University of Chicago - Chicago

Minnesota

  • Mayo Clinic - Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2015-06
Est. Completion 2026-06

What the Registry Record Tells You About NCT02884102

The ClinicalTrials.gov registry entry for NCT02884102 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% higher). The listed sponsor is Multiple Myeloma Research Foundation, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which genetic sequencing is the first listed.

NCT02884102 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Massachusetts, Michigan.

Frequently Asked Questions

What is clinical trial NCT02884102 about?

NCT02884102 is a clinical study titled "MMRF Molecular Profiling Protocol". This protocol is now being used as screening for the MyDRUG study

What is the current status of trial NCT02884102?

This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2015-06. Estimated completion is 2026-06.

What conditions does trial NCT02884102 study?

This clinical trial studies the following conditions: Multiple Myeloma, Plasma Malignancy.

What interventions are being tested in trial NCT02884102?

The interventions under investigation include: genetic sequencing (GENETIC).

Who is sponsoring clinical trial NCT02884102?

This trial is sponsored by Multiple Myeloma Research Foundation, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02884102 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.